allochol apvalkotās tabletes
pharmsol europe limited, malta - carbo activatus, nātru lapu, chole narkotiku, allii sativi spuldzes putekļu temperatūra - apvalkotā tablete
cefazolin pharmsol 1000 mg pulveris injekciju/infūziju šķīduma pagatavošanai
pharmsol europe limited, malta - cefazolīns - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg
cefepime pharmsol 1 g pulveris injekciju/infūziju šķīduma pagatavošanai
pharmsol europe limited, malta - cefepīms - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g
ceftriaxone pharmsol 1000 mg pulveris injekciju/infūziju šķīduma pagatavošanai
pharmsol europe limited, malta - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
cinnarizin sopharma 25 mg tabletes
sopharma ad, bulgaria - cinnarizīns - tablete - 25 mg
troxerutin sopharma 300 mg cietās kapsulas
sopharma ad, bulgaria - trokserutīns - kapsula, cietā - 300 mg
quinapril polpharma 10 mg apvalkotās tabletes
pharmaceutical works polpharma sa, poland - hinaprils - apvalkotās tabletes - 10 mg
quinapril polpharma 40 mg apvalkotās tabletes
pharmaceutical works polpharma sa, poland - hinaprils - apvalkotās tabletes - 40 mg
paracetamol sopharma 500 mg tabletes
sopharma ad, bulgaria - paracetamols - tablete - 500 mg